Eli Lilly Omvoh Demonstrates Sustained Long-Term Benefits in Ulcerative Colitis Up to Four Years
Eli Lilly and Company (NYSE:LLY) is one of the best growth stocks to buy now.
Eli Lilly & Co (LLY)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Fisher Asset Management Ken Fisher | 4,302,467 | $3,353,902,220 | -21% | 1.33% |
| 2. | 3,739,500 | $2,915,052,435 | +94% | 0.51% | |
| 3. | 2,051,200 | $1,598,971,936 | 9.09% | ||
| 4. | 1,720,500 | $1,341,181,365 | +5% | 0.23% | |
| 5. | Tiger Global Management LLC Chase Coleman And Feroz Dewan | 1,511,160 | $1,177,994,555 | +14% | 3.46% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $691.79 | 715 | $494,626.99 | 14,685 | 2025-08-15 | Filing | |
| $660.25 | 758 | $500,472.53 | 758 | 2025-08-13 | Filing | |
| $647.36 | 1,000 | $647,360.00 | 20,562 | 2025-08-13 | Filing | |
| $644.77 | 1,632 | $1,052,263.01 | 546,601 | 2025-08-12 | Filing | |
| $634.41 | 1,000 | $634,405.00 | 137,660 | 2025-08-12 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $857.26 | 200 | $171,451.00 | 94,536,978 | 2025-10-09 | Filing | |
| $854.96 | 835 | $713,888.26 | 94,537,178 | 2025-10-09 | Filing | |
| $854.61 | 1,473 | $1,258,833.17 | 94,538,013 | 2025-10-09 | Filing | |
| $853.20 | 1,247 | $1,063,936.66 | 94,539,486 | 2025-10-09 | Filing | |
| $852.21 | 2,472 | $2,106,655.70 | 94,540,733 | 2025-10-09 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 780,547 | $594,502,668 | 0.59% | |
| 2. | 572,946 | $437,157,798 | 0.6% | |
| 3. | 201,919 | $154,064,197 | 1.06% | |
| 4. | 140,355 | $101,969,306 | 1% | |
| 5. | 87,497 | $66,626,408 | 0.95% |
News See All
12 Best Growth Stocks to Buy Now
On October 1, Keith Lerner, Chief Investment Officer at Truist Wealth, appeared on CNBC and stated that the shutdown fears are muted, and investors are not overly concerned right now.
Guggenheim Reaffirms Its Buy Rating on Eli Lilly & Company (LLY) with Price Target of $875
The analyst noted that there was strong demand for tirzepatide in the treatment of diabetes and obesity and that the impending launch of orforglipron will support global growth.
Analyst Explains Why Eli Lilly (LLY) GLP-1 Advantage is Decreasing
Don Kaufman of TheoTrade said in a recent program on Schwab Network that Eli Lilly And Co (NYSE:LLY) edge in the GLP-1 drugs is thinning as “every” pharma company has the capacity to make drugs like...
Eli Lilly and Company (LLY) Gets Upgraded to a Buy by CFRA
Eli Lilly and Company (NYSE:LLY) is one of the best medical stocks to buy now.
Jim Cramer Put These 15 Stocks Under the Microscope
“At last, the drug companies are trying to reclaim their old mantle as the safest place to be in a slowdown.
Eli Lilly (LLY) Rated Outperform With Strong GLP-1 Prospects
Eli Lilly & Company (NYSE:LLY) ranks among the stocks with low beta that can beat market volatility.
12 Best Medical Stocks to Buy Now
On September 26, Geoff Meacham, Managing Director of Citi Research, appeared on CNBC’s “Closing Bell Overtime” to talk about President Trump’s plan to impose a 100% tariff on “all any branded...
Eli Lilly and Company (LLY) Expands Global Reach with Orforglipron Launch Plans in India
Eli Lilly and Company (NYSE:LLY) tops our list for being one of the best healthcare stocks.